Leap Therapeutics is a biopharmaceutical company based in Cambridge, MA, dedicated to developing targeted and immuno-oncology therapeutics for the treatment of various cancers. Their lead clinical candidate, DKN-01, is a humanized monoclonal antibody that targets the DKK1 protein and is being investigated for esophagogastric, gynecologic, and colorectal cancers. Additionally, they are developing FL-301, a humanized monoclonal antibody targeting Claudin18.2, for gastric and pancreatic cancer, along with other preclinical antibody programs.
With a mission to combat cancer, Leap Therapeutics is focused on understanding tumor expression, identifying new targets, and developing innovative therapies and combinations. Through their research and clinical studies, they aim to provide new treatment options for patients with DKK1 expressing tumors and contribute to the advancement of cancer care.
Generated from the website